Why is Regeneron Pharmaceuticals stock down 3.4% today?

Traders Union
All News
Stocks
Regeneron slides 3.4% today

Highlights

Shares of Regeneron Pharmaceuticals trade below short- and medium-term moving averages, indicating ongoing selling pressure.
Technical indicators give mixed signals with MACD and ADX showing positive momentum, while RSI, CCI, and HMA indicate downside risk.
Over the next five trading days, shares are likely to range between $748.14 to $774.31, with a baseline scenario of sideways movement.

Anton Kharitonov, expert at Traders Union, views Regeneron's recent 3.4% drop as a clear sign of persistent selling pressure. He is cautious given the stock's failure to hold key short- and medium-term moving averages, signaling technical fragility. Absence of positive news flow amplifies the lack of buyer conviction and exposes downside risk. Despite a long-term bullish setup above the 200-day average, momentum oscillators remain in conflict and the intraday action is notably weak. "Without a clear bullish catalyst or sustained institutional demand, I see heightened risk of further declines below $748.14," Kharitonov states.

Viktoras Karapetjanc, expert at Traders Union, highlights that even after short-term selling, Regeneron’s long-term bullish structure remains intact above the 200-day moving average. He is encouraged by the positive momentum in MACD and ADX, which shows underlying strength in the market setup. Karapetjanc views the current range as an opportunity to accumulate on dips with upside potential if $774.31 is cleared. "Further growth is likely as the market offers multiple setups for trend-following entries in this corridor," Karapetjanc asserts.

Jainam Mehta, market strategist, notes a tactical divergence between short-term weakness and the stock’s longer-term technical support. He sees possible contrarian opportunities around the $748.14 floor, especially with mixed signals from momentum indicators. "A potential breakout above $774.31 would shift the risk-reward in favor of bulls, but I would stay tactical and hedge until the range is resolved," Mehta says.

Mixed momentum as support holds above long-term average

Regeneron Pharmaceuticals is trading below its 20-day and 50-day moving averages ($801.79 and $776.76), indicating short- and medium-term pressure from sellers, but remains above the 200-day moving average ($735.68), which supports the longer-term bullish alignment. Immediate levels to watch are the near-term ceiling at $774.31 and the near-term floor at $748.14. Momentum readings are mixed; Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) point to positive momentum, while the Relative Strength Index (RSI), Commodity Channel Index (CCI), and Hull Moving Average (HMA) project downside risk. Sellers currently dominate intraday action as indicated by negative Bull/Bear Power (BBP) with an "Oversold" reading, and price action is near the low of today's range. The stock opened with a mild upside gap of about 0.2% but has slipped $26.81 or 3.4% to $761.23. Intraday volatility amplitude is 0.86%. The overall tone reflects continued selling pressure after the open, with oscillators and momentum signals in clear divergence.

Earlier, analysts noted that Regeneron Pharmaceuticals exhibited sustained bullish momentum, tempered by emergent regulatory and litigation risks. The current article signals a shift to short-term technical weakness, with a sideways bias likely until a decisive move occurs outside the $748.14 to $774.31 trading band.

Source of Data: REGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.